15 aug: Vestas har modtaget en ordre på 424 MW i Mexico
16 aug: Indre værdi af SmallCap Danmark A/S er opgjort til 88,4 kr. pr. a..
16-08-2017 07:45:00

Six-month interim report (Q2) 2017

Relateret indhold
16 feb - 
Aktier/åbning: Nordea og DSV tager teten i grønt marked
16 feb - 
Aktier/tendens: DSV får rygklap af storbank før grøn åb..
16 feb - 
ALK-Abelló får japansk godkendelse af allergitablet til..
Relateret debat
10 feb - 
ap69 har jo ellers rost aktien til skyerne, hvor vi sna..
09 feb - 
Det er tænkøligt at den får en kortvarig tur op, men så..
09 feb - 
På det her niveau kan det være relevant at samle op, is..

København, 2017-08-16 07:45 CEST (GLOBE NEWSWIRE) --

 

Bemærk venligst, at kvartalsrapporten kun foreligger på engelsk.              

Performance for the period (unaudited)

(Comparative figures for 2016 are shown in brackets. Revenue growth is measured in local currencies.

2016 comparative figures are affected by last year's market disruptions which boosted ALK's sales and earnings in Europe significantly, particularly in the second quarter. To provide a meaningful benchmark, comparisons to figures from 2015 have also been included in the report wherever relevant.)

During Q2 2017, ALK continued its investment programme focused on building-up the company in North America, securing its European leadership position and upgrading its product supply. ALK has met all its key objectives for H1 2017 and now has H1 total revenue that is 25% higher than 2015, before the market disruptions. ALK will continue to invest in expansion initiatives to deliver its long-term growth plans.   

Q2 2017 highlights:

  • Performance was in line with expectations: Growth in North America and International markets was, as anticipated, offset by declining revenue in Europe, partly following the disruptions of 2016.

  • Total revenue declined to DKK 691 million (773). When comparing this with last year, it is important to note that Q2 2016 included an extraordinary carry-over benefit of European orders worth approximately DKK 100 million which were placed in Q1 2016 but invoiced in Q2 2016.

  • European revenue was 29% higher organically than Q2 2015 'pre-market disruption' levels, representing a significant expansion of ALK's size.

  • The previously communicated SCIT capacity constraints are estimated to have negatively impacted Q2 sales by DKK 50-60 million.  

  • Operating profit (EBITDA) was DKK 16 million (159) following planned cost increases to support long-term growth mainly in the USA and in ALK's product supply operations.

  • In H1, total revenue amounted to DKK 1,480 million (1,621) and operating profit (EBITDA) was DKK 156 million (436).

Business priorities

  • Investments in the North American build-up in support of the tablet portfolio are ongoing and ALK is currently evaluating opportunities to move forward the launches of ACARIZAX® from 2018 to 2017. The US-brand name will be ODACTRA™. Meanwhile, the transfer of US product licences is still being processed by the FDA.

  • Investments in retaining market leadership in Europe continue and are showing good progress.

  • ACARIZAX® sales continue to grow strongly; development and registration activities are progressing as planned.

  • SCIT production output has now been fully restored for all major allergens, and robust inventory levels are expected to be gradually rebuilt during 2018.  

  • A strategy update will be presented in the autumn. 

2017 financial guidance

ALK's financial guidance for full-year revenue and operating profit (EBITDA) is unchanged. The free cash flow guidance has been revised, primarily due to higher tax payments and a slightly higher working capital:

  • Full-year revenue is still projected at DKK 2.8-3.0 billion (2016: DKK 3.0 billion) as European markets establish a 'new normal' following last year's disruptions.  

  • Operating profit (EBITDA) is still expected to be ~DKK 300 million.

  • Free cash flow is now expected at minus DKK 600 million or greater (previously: down to approximately minus DKK 500 million).

     

Hørsholm, 16 August 2017

ALK-Abelló A/S

 

For further information, contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014  

Today, ALK is hosting a conference call for analysts and investors at 1.30 p.m. (CEST) at which Management will review the financial results and the outlook. The conference call will be audio cast on http://ir.alk.net/. Participants in the audio cast are kindly requested to call in before 1.25 p.m. (CEST). Danish participants should call in on tel. +45 7022 3500 and international participants should call in on tel. +44 (0) 20 7572 1187 or +1 646 722 4972. Please use the Participant Pin Code: 52826656#. The conference call will also be webcast live on our website, where the related presentation will be made available shortly before the call begins.

Vedhæftet fil: FM_20_17UK_16082017.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Nordea/Nykredit: Mindre gevinst ved flytningen betyder ikke meget

16-02-2018 16:17:10
Ændringen i besparelserne ved Nordeas flytning til Finland fra Sverige betyder ikke frygtelig meget.Det vurderer analytiker ved Nykredit Markets Ricky Steen Rasmussen.Forventningerne til besparelserne i forbindelse med flytningen til Finland er blevet justeret til 0,9-1,2 mia. euro fra 1,1-1,3 mia. euro. Det oplyste Nordea i en meddelelse til fondsbørsen fredag eftermiddag.- Jeg ser ikke særlig st..

Nordea venter færre besparelser ved flytning til Finland

16-02-2018 14:18:54
Efter nøje beregninger er Nordea kommet frem til, at den forestående flytning af hovedsædet til Finland fra Sverige giver en mindre økonomisk gevinst end hidtil antaget.Nu venter den skandinaviske storbank, at nettonutidsværdien af de samlede besparelser på afviklingsgebyrer, indskydergarantier og andre midlertidige effekter af flytningen af hovedsædet udgør cirka 0,9-1,2 mia. euro. Tidligere regn..

Aktier/middag: Bred funderet opgang er modreaktion på korrektion

16-02-2018 11:19:57
De ledende danske aktier ligger fredag middag alle i grønt uden deciderede selskabsspecifikke faktorer som forklaring på de enkelte aktiers bevægelser.I toppen ligger Novozymes, Novo Nordisk og DSV.C25-indekset ligger fredag middag med en stigning på 1,9 pct. i 1142,72. Det er tredje dag i træk med løft, og indekset er indtil videre steget fire af de seneste fem handelsdage og små 5 pct. siden sid..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

ALK-Abelló B A/S 730,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. februar 2018 11:59:31
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180209.1 - EUROWEB1 - 2018-02-18 11:59:31 - 2018-02-18 11:59:31 - 1 - Website: OKAY